DEKAVIL (F8-IL10)

Dekavil is an immunocytokine consisting of a vascular targeting antibody fused to the anti-inflammatory cytokine interleukin-10 (IL10).

Dekavil has demonstrated an impressive ability to selectively localize to arthritic sites in-vivo, potently inhibiting arthritic progression. Dekavil is expected to be superior to non-conjugated recombinant IL10, a biopharmaceutical which has extensively been tested in Phase II clinical trials in chronic inflammation and which has shown efficacy for the treatment of rheumatoid arthritis.

Dekavil has entered Phase I clinical trials in combination with methotrexate for the therapy of rheumatoid arthritis in 2011.

SELECTED REFERENCES
Schwager et al., (2011) Human Reprod. 26, 2344-52
Schwager et al., (2009) Arthritis Res. Ther., 11, R142;
Trachsel et al., (2007) Arthritis Res. Ther., 9, R9;
Trachsel et al., (2007) J. Invest. Dermatol., 127, 881-886.